This trial is evaluating whether Guselkumab will improve 2 primary outcomes and 8 secondary outcomes in patients with Psoriasis. Measurement will happen over the course of Baseline, week 24.
This trial requires 350 total participants across 3 different treatment groups
This trial involves 3 different treatments. Guselkumab is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
"The risk of developing psoriasis seems to increase with age. However, there is some evidence that it may be related to the development of certain types of bacterial infection in early childhood. Genetic factors are also thought to play a role. There is no conclusive evidence of a link between psoriasis and HIV Infection. Psoriasis seems to have no cause or a multiple cause with many causes.\n" - Anonymous Online Contributor
"The only way psoriasis can be cured is if all the immune cells are removed as part of the inflammatory process of psoriasis. This is similar to what happens in a good course of immunosuppressive therapy, and may be the only way to remove the root cause of psoriasis. Patients are more likely to get a successful result if their course includes a tight regime of topical therapy." - Anonymous Online Contributor
"Symptoms and signs may appear similar to other skin disorders. When psoriasis affects a joint, symptoms include redness, warmth that is worse around the eyes or in the wrists and hands. A biopsy of the redness will help distinguish it from another condition. When skin lesions show signs of a life threatening infection, a biopsy sample is taken and tested for bacteria and fungi. The diagnosis can be made without a biopsy by using a dermatology and rheumatology consultation. Psoriasis has many causes and can be long-term in some cases, often leading to serious joint problems." - Anonymous Online Contributor
"Only 17.5 million adults in the US are affected by psoriasis a year, or 5% of individuals with skin disease. This accounts for 4.2 million clinic visits annually, and the total annual indirect costs of psoriasis are nearly $3 billion." - Anonymous Online Contributor
"There are many signs of psoriasis, all of them non-specific to the disease. Symptoms usually manifest as itching, swollen joints, skin lesions and nails, red skin, and nail psoriasis in the toes. The red, scaly patches are also a sign of psoriasis. The characteristic 'corky' (sometimes 'plaque-like') bumps can also occur. It also can affect the eyes and skin folds around the mouth, lips, and armpits. Other symptoms may include headaches, muscle aches and pains (non-specific), fatigue (common in younger patients), and weight gain (in children)." - Anonymous Online Contributor
"Dapsone is typically given for the treatment of moderate to severe cases of psoriasis.\n- Phototherapy with long-wavelength (>600 nm) UV-A or UV-B is a very effective treatment for psoriasis." - Anonymous Online Contributor
"Guselkumab is well tolerated with low rates of serious adverse events across indications. In addition, safety data suggests that guselkumab is an intriguing, powerful treatment option, and clinical development should continue." - Anonymous Online Contributor
"Women are less likely to get psoriasis than men. A larger portion of psoriasis patients develop the disease at younger ages. More than 50% of psoriasis patients develop the condition before age 20. The average ages for a 50% of psoriasis patients with disease onset in the ages of 9‐19 are as follows: 17.0 in females, 15.5 in males. The average age of 50% with disease onset before age 20 is as follows: 20.5 in females, 20.3 in males." - Anonymous Online Contributor
"Data from a recent study are consistent with a recessive gene locus affecting all forms of psoriasis, with major contribution from the HLA-Cw6 allele. This finding implicates new targets for the development of treatments for psoriasis." - Anonymous Online Contributor
"It's been just 3 months since guselkumab became commercially available. The patient group included in this open-label trial were largely young, well-to-do with a median duration of psoriasis (12.8 years) and moderate body mass index (BMI) (27.7 kg/m). In comparison with placebo (N=61), psoriatic arthritis (N=35) was significantly greater relative to placebo and all other treatment groups (relative to placebo, p<0.05; relative to adalimumab and ustekinumab, p<0.05; relative to ustekinumab, p<0.05)." - Anonymous Online Contributor
"Even moderate quantities of psoriasis are a severe disease and hence a potential cause of premature death, especially in men. The main causes of this remain unclear, but the disease is strongly associated with immunosuppression due to illness and/or medication." - Anonymous Online Contributor
"Adalimumab was not more effective in terms of safety, duration, or time to response compared with placebo. Overall, guselkumab has modest efficacy in psoriasis patients, with no obvious advantage compared with the best treatment of conventional therapeutic agents." - Anonymous Online Contributor